Who Is Diamond CBD? A Brand File on a Troubled Public-Company Name

Diamond CBD is a real, long-running company with a genuinely troubling paper trail — and the responsible thing is to describe that trail exactly, not luridly. Our F rests on two measurable things: its lab transparency is below where the industry has landed (no named lab, no per-batch verification, no confirmed full panels), and its verifiable public record carries more adverse events than any other brand we've scored. Both are real.

But "adverse record" is not the same as "proven guilty today." Most of what follows is old (2017–2019), some of it is disputed by the company and was never adjudicated, and the most serious-sounding item — a criminal stock-fraud case — was brought against individuals, with the Justice Department stating the companies were not accused. We'll mark each one. If you take nothing else from this file: a low grade here is about transparency and a documented history, not a claim that anything you'd buy today is contaminated.

Here's the genuine transparency credit, and it's a real one: because Diamond CBD operated under a publicly traded company, its corporate skeleton is documented in a way most private hemp brands' never are. The operating brand is Diamond CBD, Inc. (a Delaware corporation), under a Florida subsidiary, under a public parent — Diamond Wellness Holdings, Inc. (formerly PotNetwork Holdings, Inc.), which trades under the ticker POTN and is headquartered in Fort Lauderdale, Florida. You can read that chain in securities filings.

This is the single claim most often repeated about Diamond CBD, and the one most important to state carefully, because getting it wrong would be both unfair and legally reckless. Here is what is actually true:

• What happened: a peer-reviewed 2018 study by researchers at Virginia Commonwealth University (published in a forensic-science journal) reported that several products — including some Diamond CBD "Liquid Gold" items — purchased around 2017 contained a synthetic cannabinoid (5F-ADB, a "K2/Spice"-class compound), and one contained the cough-suppressant DXM. (Note: this originates from the VCU study, not "Project CBD," a misattribution we won't repeat.)
• The company's response: Diamond CBD's then-CEO disputed the finding, said retests found no such compounds, and attributed the result to older 2017-era formulas and supply chain.
• The disposition: it was a peer-reviewed lab finding — meaningfully more than a bare rumor — but it was never adjudicated, produced no recall and no enforcement action tied to it, and the company contests it.

Given that history, you'd want Diamond CBD's present-day testing to be airtight. It isn't. It clears the lowest bar — some COAs exist, and the brand says products are "third-party tested" — but it misses the markers serious buyers now expect:

• No lab is named. The site references only "a third-party lab," without identifying the testing partner — so you can't assess the lab's accreditation or credibility.
• No real per-batch verification. COAs are searchable by product name, not by batch or lot, which means a search can return a report that doesn't match the specific bottle in your hand. We found no QR-to-batch system.
• Full panels aren't confirmed. The copy emphasizes potency/label-match; it doesn't clearly publish the pesticide, heavy-metal, solvent, and microbial results that a full contaminant panel includes, and independent reviewers have flagged missing contaminant testing.

For most brands, weak COA hygiene is a transparency demerit. For one carrying a disputed contamination history, the inability to verify a named lab and a full panel on the exact batch you're buying is a more serious gap — and it's the biggest single reason the safety pillar scores low.

On manufacturing, Diamond CBD markets itself as "a premier manufacturer," but discloses no facility, no statement of whether it makes its own product or uses co-packers, no current GMP or ISO certification, and no FDA facility registration. On sourcing, it's "American-grown" with no state, farm, or supplier named — set against a documented history of independent reviewers questioning its label accuracy (including a finding that some "CBD" gummies were heavier on melatonin than CBD). On people, its last full securities filing reported a small operation of about 13 employees at the Fort Lauderdale HQ; current headcount isn't disclosed, and no Glassdoor rating surfaced. Across all three, the pattern is the same: marketing claims without the verifiable detail behind them.

Diamond CBD's broader record is the heaviest in these files, so we'll sort it precisely by what kind of event each one is:

• 2019 FDA + FTC warning (proven regulatory action). In March 2019 the FDA sent the parent (then PotNetwork) a warning letter over unapproved drug claims — marketing CBD products as treating diseases like Alzheimer's and diabetes — and the FTC joined it in April 2019. The company says it removed the claims. A warning letter is a regulatory allegation the company addressed, not a court judgment.
• Settled mislabeling class action (settled, no admission). A 2019 consumer class action (Potter v. PotNetwork Holdings) alleged CBD-content mislabeling; it was settled ("amicably resolved," terms undisclosed) with no admission of liability.
• Criminal stock-fraud case — against individuals, NOT the company. In 2019, the Justice Department criminally charged three individuals connected to the penny-stock parent (and two other tickers) in an alleged "pump-and-dump." The DOJ explicitly stated the companies themselves were not accused of wrongdoing. These are allegations against people; we did not independently confirm the final convictions or sentences, so we assert none. This is emphatically not a finding against the brand or its products.
• SEC deregistration + Caveat Emptor (proven, factual). As above: registration revoked June 2023 for reporting delinquency; OTC "Caveat Emptor" flag. Public record.
• BBB / recalls: a BBB rating in the "B" range with a modest complaint history; no product recalls found.

Read together: a real company with real revenue in its heyday (it reported tens of millions at its 2018 peak), that took some transparency steps (it pursued public registration; it removed FDA-cited claims; it settled the class action) — but whose verifiable record is, on balance, the most troubled in this set, even after every item is framed conservatively.

In our view, Diamond CBD is a brand whose own paper trail is the strongest argument for caution — and we reach that view without overstating a single item. The F isn't built on the scariest possible reading of its history; it's built on two measured facts: present-day lab transparency that falls below industry norms (no named lab, no per-batch verification, unconfirmed full panels), and a verifiable public record — disputed contamination study, FDA/FTC warnings, settled mislabeling suit, deregistered Caveat-Emptor shell, principals criminally charged — that is heavier than any other brand here. The genuine credit, a documented corporate structure, can't outweigh that.

If you're considering Diamond CBD, our honest guidance is to insist on what the brand currently can't fully give you: a named, accredited lab and a full-panel COA matched to your exact batch. Until that exists, there are many brands in these files — graded far higher — that make verification easy. An F (35/100), assigned carefully and with every adverse item labeled proven, disputed, or old. The full methodology shows every point; if Diamond CBD names its lab and publishes full per-batch panels, we'll re-grade it on those facts (see the notice below).